VEGFA and ovarian carcinoma: The reported benefits of endocrine therapy in ovarian cancer have been inconsistent, and its potential synergy with other targeted therapies, such as PARP inhibitors or anti-vascular endothelial growth factor (VEGF) antibodies, remains uncertain.